Cancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.
MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR, 999078, China.
Mol Diagn Ther. 2024 Nov;28(6):669-702. doi: 10.1007/s40291-024-00734-w. Epub 2024 Aug 22.
In recent years, bispecific antibodies (BsAbs) have emerged as a promising therapeutic strategy against tumors. BsAbs can recruit and activate immune cells, block multiple signaling pathways, and deliver therapeutic payloads directly to tumor sites. This review provides a comprehensive overview of the recent advances in the development and clinical application of BsAbs for the treatment of solid tumors. We discuss the different formats, the unique mechanisms of action, and the clinical outcomes of the most advanced BsAbs in solid tumor therapy. Several studies have also analyzed the clinical progress of bispecific antibodies. However, this review distinguishes itself by exploring the challenges associated with bispecific antibodies and proposing potential solutions. As the field progresses, BsAbs hold promise to redefine cancer treatment paradigms and offer new hope to patients with solid tumors.
近年来，双特异性抗体（BsAbs）作为一种有前途的肿瘤治疗策略已经出现。BsAbs 可以募集和激活免疫细胞，阻断多个信号通路，并将治疗有效载荷直接递送至肿瘤部位。本综述全面概述了 BsAbs 在治疗实体瘤方面的最新进展和临床应用。我们讨论了不同的形式、独特的作用机制以及实体瘤治疗中最先进的 BsAbs 的临床结果。一些研究还分析了双特异性抗体的临床进展。然而，本综述的独到之处在于探讨了与双特异性抗体相关的挑战，并提出了潜在的解决方案。随着该领域的进展，BsAbs 有望重新定义癌症治疗范例，为实体瘤患者带来新的希望。
